Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

hMSCs

Phase 2Biologic

MMarilyn Glassberg

1

Indications

3

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Ischemic Dilated CardiomyopathyActive, not recruiting

Non-Ischemic Dilated CardiomyopathyPhase 2

Active, not recruiting

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Non-Ischemic Dilated Cardiomyopathy

NCT04476901

Clinical

Trials by Indication[1]

Asthma1 trial

Allogeneic Human Cells (hMSC) Via Intravenous Delivery in Patients With Mild Asthma

Terminated·MMarilyn Glassberg·Phase 1·NCT03137199·3 enrolled

Cystic Fibrosis1 trial

Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non-Cystic Fibrosis Bronchiectasis

Completed·MMarilyn Glassberg·Phase 1·NCT02625246·6 enrolled

Non-ischemic Dilated Cardiomyopathy1 trial

A Phase IIB Randomized, Placebo-Controlled, Multicenter Study of the Comparative Efficacy and Safety of Administration of Allogeneic-MSC Versus Placebo in Patients With Non- Ischemic Dilated Cardiomyopathy

Active, not recruiting·JJoshua M Hare·Phase 2·NCT04476901·107 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for hMSCs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — hMSCs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for hMSCs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Marilyn Glassberg company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: MMarilyn Glassberg

Related News